MD13

Overview

MD13 is a MIF PROTAC degrader with a DC 50 of approximately 100 nM. MD13 induces ubiquitination and degradation of MIF by recruiting the Cereblon Cullin RING E3 ubiquitin ligase complex. MD13 inactivates the MAPK pathway and induces G 2 /M phase cell cycle arrest. MD13 exhibits antiproliferative effects in 3D tumor spheroid models. MD13 can be used in lung cancer-related research. (Pink: Macrophage migration inhibitory factor (MIF) Target protein ligand; Blue: Cereblon ligand ( HY-10984 ); Black: linker).

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Lung Cancer | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > Macrophage migration inhibitory factor (MIF) | Products > Signaling Pathways > p38 MAPK

Product Information

• Catalog No.: HY-148117
• CAS No.: 2758431-97-7
• Molecular Formula: C35H35N5O8
• Molecular Weight: 653.68
• Purity: 99.96%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source